Oncology Central

The benefits of including expansion cohorts in Phase I oncology clinical trial design


The primary objective of a Phase I study is to determine the recommended Phase II dose (RP2D) of a new drug or combination of agents. Increasingly, these studies are enrolling additional patients once the RP2D has been determined to further characterize the toxicity and efficacy profile, as well as the pharmacokinetic (PK) and pharmacodynamic (PD) properties of the studied agent/combination. Typically referred to as an expansion cohort, this design is often employed in specific patient populations with either a particular histology or molecular aberration.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.